文献速递白血病

靶向RIOK2 ATP酶活性导致急性髓系白血病蛋白合成减少与细胞死亡

Targeting RIOK2 ATPase activity leads to decreased protein synthesis and cell death in acute myeloid leukemia.
PubMed 文献 · Blood · 2022-01-01

急性髓系白血病(AML)亟需新疗法。研究通过激酶组CRISPR-Cas9筛选发现RIOK2为潜在靶点,RIOK2缺失或ATP酶功能抑制可降低白血病细胞蛋白合成、引起核糖体不稳定并诱导凋亡,小分子抑制剂在体内外均显示抗白血病效果。

要点

  • RIOK2是AML的潜在治疗靶点,其ATP酶功能对白血病细胞存活必需。
  • RIOK2缺失降低蛋白合成、致核糖体不稳定并诱导白血病细胞凋亡。
  • 小分子抑制剂靶向RIOK2在体内外均抑制白血病细胞生长。

核心结论

  • 靶向RIOK2 ATP酶活性可减少蛋白合成并诱导AML细胞凋亡,为AML治疗提供概念验证。

研究设计与样本

  • 研究采用聚焦结构域的激酶组CRISPR-Cas9筛选,鉴定治疗AML的蛋白激酶靶点,并识别RIOK2为潜在新靶点。

主要发现

  • RIOK2缺失导致白血病细胞蛋白合成减少、核糖体不稳定并随后凋亡,而成纤维细胞未出现此现象。
  • RIOK2的ATP酶功能对细胞存活是必需的。
  • 使用小分子抑制剂对RIOK2进行药理抑制同样导致蛋白合成丧失和凋亡,并在体内影响白血病细胞生长。

临床怎么用

  • RIOK2可作为AML潜在治疗靶点,其ATP酶活性抑制可能成为新的治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Novel therapies for the treatment of acute myeloid leukemia (AML) are urgently needed, because current treatments do not cure most patients with AML. We report a domain-focused, kinome-wide CRISPR-Cas9 screening that identified protein kinase targets for the treatment of AML, which led to the identification of Rio-kinase 2 (RIOK2) as a potential novel target. Loss of RIOK2 led to a decrease in protein synthesis and to ribosomal instability followed by apoptosis in leukemic cells, but not in fibroblasts. Moreover, the ATPase function of RIOK2 was necessary for cell survival. When a small-molecule inhibitor was used, pharmacological inhibition of RIOK2 similarly led to loss of protein synthesis and apoptosis and affected leukemic cell growth in vivo. Our results provide proof of concept for targeting RIOK2 as a potential treatment of patients with AML.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Messling JE, Agger K, Andersen KL, et al. Targeting RIOK2 ATPase activity leads to decreased protein synthesis and cell death in acute myeloid leukemia. Blood. 2022. PMID: 34359076. doi:10.1182/blood.2021012629

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。